Activation of N-methyl-D-aspartate (NMDA) receptors in the spinal dorsal horn neurons is a key process related to sensory transmission, neural plasticity and pathogenesis of pain. In this study, we investigated how activation of NMDA receptors in spinal substantia gelatinosa neurons is regulated by glutamate re-uptake through glutamate transporters located in the astrocytic and neuronal plasma membranes. Using visualized whole-cell patch recording techniques, NMDA excitatory postsynaptic currents evoked by graded peripheral inputs in spinal substantia gelatinosa neurons of spinal slices from young adult rats were analyzed before and after combined inhibition of glial and neuronal glutamate transporters by DL-threo-β-benzyloxyaspartate (TBOA). Blockade of glutamate transporters increased the number and duration of NMDA receptors activated by weak and by strong primary afferent inputs as well as by exogenous glutamate. The enhancement in activation of NMDA receptors induced by TBOA was greater in neurons that have weaker synaptic input at baseline. Impaired glutamate uptake increased the open probability of NMDA channels, and caused glutamate spillover outside the active synapses, leading to activation of extrasynaptic NMDA receptors and/or receptors located in neighboring synapses. Finally, blockade of glutamate transporters resulted in an increased proportion of NR2B subunit activation induced by peripheral input, and this increase was further augmented by stronger afferent input. These data indicate that glutamate transporters regulate spatiotemporal and intensity coding for sensory input and prevent excessive activation of glutamate receptors in the spinal dorsal horn. It is suggested that remedying dysfunctional glutamate transporters may be a potential new avenue to prevent the pathogenesis of pain.
Activation of N-methyl-D-aspartate (NMDA) receptors in the spinal dorsal horn neurons is a key process related to sensory transmission, neural plasticity and pathogenesis of pain. For example, spinal topical application of NMDA elicits nociceptive behaviors in awake animals (Aanonsen and Wilcox 1987; Kontinen and Meert 2002) and activation of dorsal horn neurons in intact anesthetized animals (Davies and Watkins 1983) . More importantly, activation of NMDA receptors in the spinal dorsal horn is related to almost all forms of pathological pain induced by tissue injury or inflammation (Ren and Dubner 2007) . For decades, researchers have gone to great lengths to investigate the mechanisms related to modulation and activation of NMDA receptors and their intracellular signaling pathways. In comparison, little is known about how the glutamate clearance process regulates activation of NMDA receptors in the spinal dorsal horn.
Glutamate released from presynaptic neurons is not metabolized extracellularly;
rather, clearance of glutamate in the synaptic cleft and homeostasis of extracellular glutamate are ensured by a family of glutamate transporters located in the plasma membranes of both glial cells and neurons that re-uptake glutamate from the extracellular space into the cells. Glutamate uptake by glutamate transporters is driven by the electrochemical gradients of Na + and K + across the plasma membrane (Danbolt 2001; Gegelashvili et al. 2001) . Three subtypes of glutamate transporters exist in the spinal cord, including two glial glutamate transporters (glutamate/aspartate transporter, GLAST; glutamate transporter 1, GLT-1) and one neuronal glutamate transporter, excitatory amino acid carrier 1 (EAAC1). GLAST is highly concentrated in lamina I and II, whereas GLT-1 and EAAC1 are expressed diffusely throughout the dorsal and ventral 4 horns (Furuta et al. 1997; Mao et al. 2002; Seal and Amara 1999; Sung et al. 2003; Tao et al. 2004; Vera-Portocarrero et al. 2002; Weng et al. 2005) . Recent studies show that hyperalgesia induced by nerve injury or chemotherapy (paclitaxel) is associated with deficiencies in glutamate transporter protein expression (Sung et al. 2003; Weng et al. 2005 ) and glutamate uptake function (Binns et al. 2005) .
The role of glutamate transporters in pain signaling was further validated in behavioral and electrophysiological experiments when deficiency in glutamate re-uptake was induced by selective glutamate transporter blockers. Pharmacological inhibition of glutamate transporters in the spinal cord elevates spinal extracellular glutamate concentrations (Liaw et al. 2005 ) and produces spontaneous nociceptive behaviors and hypersensitivity to mechanical and thermal stimuli (Liaw et al. 2005; Weng et al. 2006) .
Such nocifensive behaviors could be significantly blocked by NMDA or non-NMDA receptor antagonists (Liaw et al. 2005 ). In addition, spinal wide dynamic range neurons exhibit increased spontaneous activities, innocuous and noxious stimulus-evoked responses and prolonged after-discharges following inhibition of glutamate transporters (Weng et al. 2006) . Spinal synaptic mechanisms underlying the functional alterations induced by deficient glutamate uptake were revealed by our recent study showing that blockade of glial GLT-1 results in enhanced activation of α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors in the spinal lamina II neurons, which is due at least in part to glutamate spillover and activation of AMPA receptors in neighboring synapses (Weng et al. 2007) .
In this study, we investigated the role of glutamate transporters in regulation of NMDA receptor activation in spinal substantia gelatinosa (SG) neurons by functional blocking all three glutamate transporters in the spinal cord with a transporter blocker, DL-threo-β-benzyloxyaspartate (TBOA). We found that glutamate transporters regulate the period and number of NMDA receptors activated by primary afferent input in the spinal SG neurons, and prevent glutamate spillover to activate NMDA receptors outside the active synapses.
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METHODS
All experiments were approved by the Institutional Animal Care and Use Committee at The University of Texas M. D. Anderson Cancer Center and were fully compliant with the National Institutes of Health Guidelines for Use and Care of Laboratory Animals.
Spinal slice preparation
Young adult male Sprague Dawley rats (140-170 g) were deeply anesthetized with halothane inhalation and a laminectomy was made for removal of the lumbar spinal cord. The lumbar spinal cord section was placed in ice-cold sucrose artificial cerebrospinal fluid (aCSF) pre-saturated with 95% O 2 and 5% CO 2 . The sucrose aCSF contained 234 mM sucrose, 3.6 mM KCl, 1.2 mM MgCl 2 , 2.5 mM CaCl 2 , 1.2 mM NaH 2 PO 4 , 12.0 mM glucose, and 25.0 mM NaHCO 3 . The pia-arachnoid membrane was removed from each section. The L4-5 spinal segment, identified by the lumber enlargement and large dorsal roots, was attached with cyanoacrylate glue to a cutting support, which was then glued onto the stage of a vibratome (Series 1000, Technical Products International, St. Louis, MO). Transverse spinal cord slices (400 µm) were cut in the ice-cold sucrose aCSF and then pre-incubated in Krebs solution oxygenated with 95% O 2 and 5% CO 2 at 35°C for at least 2 h before they were transferred to the recording chamber. The Krebs solution contained 117.0 mM NaCl, 3.6 mM KCl, 1.2 mM MgCl 2 , 2.5 mM CaCl 2 , 1.2 mM NaH 2 PO 4 , 11.0 mM glucose, and 25.0 mM NaHCO 3 .
Whole cell voltage-clamp recordings
Following pre-incubation, a single slice was placed in the recording chamber (1.5 ml in volume), perfused with Krebs solution at 35°C and saturated with 95% O 2 and 5% CO 2 . Borosilicate glass recording electrodes (resistance, 3-5 MΩ) were pulled and filled with internal solution containing 110 mM Cs 2 SO 4 , 2.0 mM MgCl 2 , 0.5 mM CaCl 2 , 5.0 mM HEPES, 5.0 mM EGTA, 5.0 mM ATP-Mg, 0.5 mM Na-GTP, and 10 mM lidocaine N-ethyl bromide (QX314), adjusted to pH 7.2 to 7.4 with 1 M CsOH (290-300 mOsm).
QX314 was added to the internal solution to suppress the action potential generation from the recorded cell. The recording electrodes were directed to the spinal lamina II (SG) region, readily identified by its distinct translucent appearance under a microscope. Live dorsal horn neurons were visualized with an infrared Nomarski microscope system (Leads Instruments, Inc., Texas, USA) and approached with a 3-dimensional motorized manipulator (Sutter Instrument Company, California, USA), and whole-cell configurations were established by applying moderate negative pressure after electrode contact (Nakatsuka et al. 2003) . A seal resistance of ≥ 2 GΩ and an access resistance of 20-35 MΩ were considered acceptable (Weng et al. 2006; Wu et al. 2005) . The series resistance was optimally compensated by ≥70% and constantly monitored throughout the experiments. Experiments showing any evidence of loss of voltage control were discarded. Signals were amplified with an amplifier (Axopatch 700B, Molecular Devices, California, USA) and displayed and stored in computer.
Excitatory postsynaptic currents (EPSCs) were evoked by constant-current electrical stimuli (0.2 ms duration, repeated every 45 s) applied through a concentric bipolar stimulating electrode placed at the attached dorsal root or root entry zone (Weng 8 et al. 2006; Yoshimura and Nishi 1993) . NMDA receptor currents were isolated by including 6,7-dinitroquinoxaline-2,3-dione (DNQX, 10 µM), bicuculline (10 µM) and strychnine (5 µM) in the external solution to block non-NMDA glutamate receptors (AMPA and kainate receptors), GABA A receptors and glycine receptors, and holding membrane potential at +40 mV to remove the voltage-dependent Mg 2+ block at NMDA receptors. In a subset of experiments, NMDA EPSCs were evoked by 50 µM L-glutamate injected onto the recorded neuron by puff-application (pressure: 3 p.s.i.; duration: 20 ms, repeated every 60 s) through a glass pipette with opening tip size of 8-12 µm. One neuron was recorded per each spinal slice, and two to three slices from each rat were used for recording. 
Materials
Data analysis
Data were recorded with Axopatch 700B amplifiers, digitized at 10 kHz and analyzed offline. Three to four EPSCs evoked by electrical stimulation or by puffed glutamate, at baseline and in the presence of tested drugs, were averaged. To measure time constants for the decay phase of NMDA EPSCs, the decay phase was fitted with monoexponential function, and time constants were measured (Weng et al. 2007 ).
Clampfit 10.2 software (Molecular Devices) was used to detect and measure the amplitude, duration and time constants of averaged EPSCs. Data are presented as means ± standard error (S.E.). Student's t test was used to determine statistical differences between measurements before and after tested drugs (paired t test) or between groups (nonpaired t test). Correlation tests and analysis of variance (ANOVA) with repeated measurements followed by Tukey post hoc tests were used when suitable. A p value < 0.05 was considered statistically significant.
RESULTS
Combined inhibition of neuronal and glial glutamate transporters increased the amplitude and duration of NMDA EPSCs in synapses responding to weak or strong primary afferent inputs
To investigate the impact of impaired glutamate uptake on activation of NMDA receptors in synapses that transmit weak primary afferent input and in synapses that respond to strong primary afferent input, responses of NMDA receptors in the spinal SG neurons to graded primary afferent inputs were evoked by stimulating the dorsal root (or root entry zone) at two different stimulating intensities: (1) two times activation threshold (2T), and (2) maximum intensity. The threshold was defined as the minimum intensity required for evoking a visible NMDA EPSC, while maximum intensity was a stimulating intensity that evoked a maximum NMDA EPSC response in the recorded neuron. We recorded evoked NMDA EPSCs prior to and after combined blockade of glial and neuronal glutamate transporters. The transporters were blocked by bath-perfusing a glutamate transporter blocker TBOA (concentration in the recording chamber: 50 µM).
TBOA specifically blocks glutamate transporters without any effects on glutamate receptors or presynaptic release of glutamate (Demarque et al. 2004; Jabaudon et al. 1999 Figure 1A and B ). The EPSCs recorded in the presence of TBOA were caused entirely by activation of NMDA channels, since they were completely abolished by a selective NMDA receptor antagonist, D-AP5 (100 µM) (tested in five neurons).
The percentage increases induced by TBOA in the amplitude of NMDA EPSC evoked by 2T stimuli were inversely correlated with their baseline amplitudes, but positively correlated with the baseline ratio between the amplitudes evoked by maximum stimulation and the amplitudes evoked by 2T stimulation ( Figure 1C ). No clear correlation was found between the percentage changes in the amplitude induced by TBOA and the baseline amplitude evoked by maximum stimulation. Regardless of the baseline EPSC amplitudes evoked by 2T or maximum stimulation, the duration of NMDA EPSCs for all neurons recorded were increased by at least 48.37% in the presence of TBOA. The overall changes (% of baseline) induced by TBOA in EPSC amplitude (209.53±36.10%), duration (355.25±66.57%), decay time constant (365.89±70.79%) and peak latency (258.21±35.84%) evoked by 2T stimulation were not significantly different from those evoked by maximum stimulation (amplitude: 282.51±65.09%; duration: 398.69±40.51%; decay time constant: 331.30±49.55%; peak latency: 300.04±44.80%). These results indicate that glutamate transporters regulate the NMDA EPSC amplitude and the duration of NMDA EPSCs in synapses activated by weak or strong primary afferent inputs, and that the net gain in the amplitude of NMDA EPSCs induced by impaired glutamate transporters is much higher in neurons receiving weak synaptic input than in neurons receiving strong synaptic input at baseline.
Combined inhibition of glial and neuronal glutamate transporters enhanced activation of NMDA receptors evoked by exogenous glutamate application
The role of glutamate transporters in synaptic transmission depends on individual synaptic structures (Danbolt 2001 (Figure 5A and C) . In normal conditions, inhibition induced by Ro 25-6981 (1 µM) on the NMDA EPSCs evoked by maximum stimuli was slightly stronger than that evoked by 2T stimuli, though the difference did not reach statistical significance ( Figure 5C ).
The NR2B component of the entire NMDA EPSC was significantly increased upon blockade of glutamate transporters. In comparison with its inhibitory effects in normal conditions, Ro 25-6981 (1 µM) produced significantly stronger inhibition on the NMDA EPSC amplitudes and duration evoked by 2T (amplitude reduced by 54.44±7.08%, duration by 31.39±6.51%, n=7) and maximum stimuli (amplitude reduced by 69.40±6.63%, duration by 50.05±4.76%) in the presence of TBOA (50 µM) ( Figure   5 ). Ro 25-6981 also induced significantly stronger inhibition on the decay time constant of NMDA EPSCs elicited at 2T stimulation in the presence of TBOA (34.53±5.63%) than in normal conditions. In the presence of TBOA, furthermore, the inhibition induced by Ro 25-6981 (1 µM) on the NMDA EPSC amplitude and duration evoked by maximum stimuli was significantly stronger than the Ro 25-6981 (1 µM)-induced inhibition on those evoked by 2T stimuli (Figure 5 ). These data indicate that, in normal synaptic transmission, the majority of NMDA subunits activated by primary afferents are not NR2B subunits (most likely NR2A subunits), but with deficient glutamate uptake the balance between activation of NR2B subunits and other subunits tilted toward NR2B subunits, making NR2B a major NMDA subunit activated by glutamate released from primary afferents.
DISCUSSION
The present study reveals how impaired glutamate uptake by glutamate transporters affects activation of NMDA receptors in spinal SG neurons. First, we demonstrated that activation of NMDA receptors by primary input on the spinal SG neurons is restricted by glutamate uptake carried out by glutamate transporters and that impairment of glutamate transporters leads to an increased duration and amplitude of NMDA EPSCs elicited by primary afferent inputs or exogenous glutamate. Second, we provided evidence that such increased activation of NMDA receptors is due to glutamate spillover that activates NMDA receptors located outside the active synapses and increases open probability of NMDA channels. Third, we showed that deficiency in glutamate uptake leads to an increased proportion of NR2B subunit activation in NMDA EPSCs and that this increase is further augmented by stronger afferent input. These data strongly indicate that an intact glutamate uptake transport system is critical in keeping accurate spatiotemporal and intensity coding in glutamatergic synaptic transmission and preventing abnormal activation of NMDA receptors in the spinal dorsal horn. These findings also suggest that reversing impaired glutamate uptake may be a potential new avenue to relieve the pathological pain related to abnormal activation of NMDA receptors. EPSCs, suggesting that diffusion of glutamate is a key process in terminating glutamate action on glutamate receptors. In most synapses, however, glutamate diffusion is restricted by glial cells wrapping the synapse (Danbolt 2001; Halassa et al. 2007; Panatier et al. 2006 ). In such synapses, glutamate transporters play a critical role in regulating activation of glutamate receptors, as demonstrated by the fact that blockade of glutamate uptake increases both the amplitude and duration of AMPA EPSCs in postsynaptic neurons (Overstreet et al. 1999; Takayasu et al. 2004 ).
Regulation of NMDA receptor activation by glutamate transporters
The regulation by glutamate transporters of activation of AMPA receptors (Weng et al. 2007) and NMDA receptors in the spinal SG neurons are consistent with the anatomical synaptic structures in the spinal SG neurons, whose synapses are reportedly wrapped by glial cells (Kerr 1975) . Interestingly, further analysis in the present study showed that the degree of enhancement induced by TBOA in activation of NMDA receptors was greater in neurons that had weak synaptic input at baseline. This indicates that the enhanced synaptic inputs caused by impaired glutamate uptake were greater for weak synaptic connections than for strong synaptic connections, consistent with a widely held notion that the effect of uptake block on synaptic transmission is related to the strength of synaptic connections (Marcaggi and Attwell 2004) . In our recent report, we also noted that, upon inhibition of glutamate transporters, the AMPA EPSC amplitudes recorded from spinal SG neurons were increased in neurons with weak synaptic input but decreased in neurons with strong synaptic input (Weng et al. 2007) . We found in the present study, on the other hand, that blockade of glutamate transporters increased NMDA EPSC amplitude in neurons receiving either weak or strong synaptic input. These data reinforce our recent conclusion that desensitization of AMPA receptors contributes to reduction of AMPA EPSC amplitude (Weng et al. 2007 ) during blockade of glutamate transporters, and are consistent with a general notion that NMDA receptors are much less vulnerable to desensitization induced by glutamate than AMPA receptors (Dingledine et al. 1999) .
Mechanisms underlying enhanced activation of NMDA receptors induced by blockade of glutamate transporters
The macroscopic NMDA receptor-mediated peak current amplitude (I peak ) recorded from a cell is determined by the following equation: In another way, the NMDA receptors recruited additionally should be located inside the synapse activated at baseline. This notion is based on the following facts. Of the 182.51 % increase in the NMDA EPSC peak amplitude in the presence of TBOA, 26.23% came from activation of NMDA receptors outside the original active synapses, and 19.95% were caused by an increase in the channel open probability (Po). The remaining difference must come from activation of NMDA receptors inside the active synapse at baseline. Hence, it is conceivable that not all the NMDA receptors located inside the synapse responding to afferent input in spinal SG neurons are occupied fully by glutamate released from presynaptic sites at the baseline (i.e., unsaturated synaptic NMDA receptors) and that impaired glutamate uptake leads to accumulation and dwelling of glutamate in the synaptic cleft that in turn leads to glutamate binding of the unsaturated synaptic NMDA receptors. This is in line with recent studies showing that 24 NMDA receptors at hippocampal synapses are not generally saturated by synaptically released glutamate (Ishikawa et al. 2002; McAllister and Stevens 2000) .
Functional considerations
The SG (lamina II) (Molander et al. 1984; Rexed 1952) Taken together, our present and previous studies indicate that spinal synaptic independence and temporal and intensity coding for sensory input rely on an intact glutamate uptake system, and suggest remedying the impaired glutamate uptake may be a potential new avenue toward treatment of pathogenesis of pain. 
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